Journey Medical CORP

Journey Medical Corporation announced first quarter 2026 financial results, reporting a 21% year-over-year increase in total revenues to $16.0 million, driven by strong performance in Emrosi.

Journey Medical Corporation has secured contracts with three major group purchasing organizations, expanding Emrosi access to 85% of U.S. commercial lives.

Journey Medical Corporation announced full-year 2025 financial results, reporting a 10% revenue increase driven by the successful launch of Emrosi, alongside improved gross margins and reduced net loss.

Journey Medical Corporation announced robust third-quarter 2025 financial results, driven by a 21% year-over-year revenue increase and significant growth in its key dermatology product, Emrosi.

Journey Medical Corporation amended its credit agreement, extending the term loan maturity to June 2028 and revising principal repayment terms based on revenue thresholds.

Journey Medical Corporation has entered into a new At Market Issuance Sales Agreement to potentially sell up to 3,750,000 shares of common stock, replacing a prior agreement.

Journey Medical Corporation reported a 21% increase in total revenue for the first quarter of 2026, driven by strong performance in Emrosi, despite an overall net loss.

Journey Medical Corporation reports increased total revenue driven by the Emrosi launch, despite declines in legacy products, while extending its credit facility maturity and addressing going concern doubts.

Journey Medical Corporation reported a slight revenue increase for Q2 2025 driven by the Emrosi launch, but faces recurring losses and a 'going concern' warning.

Journey Medical Corp reports its Q1 2025 financial results, highlighting the commercial launch of Emrosi and a slight increase in total net product revenues compared to Q1 2024.

Journey Medical Corporation's Q3 2024 results show a decrease in product revenue, offset by a gain on debt extinguishment and the FDA approval of Emrosi.

Journey Medical Corporation's Q2 2024 results show a decrease in revenue and a net loss, but also a reduction in operating expenses and a new loan facility.

Journey Medical Corp's 2024 10-K filing details the company's financial performance, strategic initiatives, and the FDA approval of Emrosi for rosacea treatment.

Journey Medical Corporation's 2023 annual report details financial performance, strategic initiatives, and regulatory progress, including a new credit facility and a license agreement.

Journey Medical Corp director Jayne Toledano Miranda was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Journey Medical Corp. director Justin Adam Smith was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Michael Cooper Pearce, a Director at Journey Medical Corp, was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Journey Medical Corp reports a grant of 10,000 restricted stock units to Director Lindsay A. Rosenwald, with vesting scheduled for June 25, 2027.

Journey Medical Corporation Chief Operating Officer Ramsey Alloush was granted 46,863 restricted stock units and 62,795 stock options.

CFO Joseph Benesch was granted 28,907 restricted stock units and 41,860 stock options as part of the company's 2015 Stock Plan.

Journey Medical Corporation has scheduled its 2026 Annual Meeting of Stockholders for June 24, 2026, to elect directors and ratify its independent auditor.

Journey Medical Corporation's annual meeting will be held virtually on June 24, 2025, with stockholders voting on director elections, auditor ratification, and certificate of incorporation amendments.

Journey Medical Corporation will hold its Annual Meeting of Stockholders virtually on June 24, 2025, to vote on key proposals including the election of directors, ratification of the company's auditor, and an amendment to the company's certificate of incorporation.

Journey Medical Corporation's annual meeting will be held virtually on June 25, 2024, and stockholders are encouraged to vote on key proposals.

Journey Medical Corporation is holding its Annual Meeting of Stockholders virtually on June 25, 2024, to vote on the election of directors, ratification of the independent auditor, and an amendment to the company's stock plan.

Vanguard Capital Management has disclosed a beneficial ownership of 774,556 shares, representing 3.59% of the outstanding common stock of Journey Medical Corp.

Wasatch Advisors LP has reported beneficial ownership of 2,858,930 shares, representing 13.3% of the class, in Journey Medical Corp as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.65% of Journey Medical Corp's common stock as of March 31, 2026.

Wasatch Advisors LP has reported beneficial ownership of 2,133,370 shares, representing 10.0% of the outstanding common stock of Journey Medical Corp.

Wasatch Advisors LP has increased its beneficial ownership in Journey Medical Corp to 6.7% of common stock, holding over 1.15 million shares.

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have disclosed a passive beneficial ownership of 8.0% in Journey Medical Corporation's common stock.